We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
KBI Biopharma Acquires Biologics Operations in Colorado
News

KBI Biopharma Acquires Biologics Operations in Colorado

KBI Biopharma Acquires Biologics Operations in Colorado
News

KBI Biopharma Acquires Biologics Operations in Colorado

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "KBI Biopharma Acquires Biologics Operations in Colorado"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

KBI Biopharma, Inc. (KBI) has signed an agreement with Merck & Co., Inc. (known as Merck in the United States and Canada) to acquire Merck’s microbial process development and manufacturing operations in Boulder, Colorado, effective May 1, 2014.

Under the agreement, KBI will provide ongoing development and manufacturing services to Merck, as well as to third party customers.

“We are very pleased to continue to advance our partnership with Merck, and to welcome this very highly regarded team of scientists in Boulder to the KBI team,” stated Joe McMahon, KBI’s President and CEO.

McMahon continued, “KBI will now offer expanded microbial development and manufacturing services up to 1500L scale, as well as continuing to offer our current full range of process development, analytical and formulation development and mammalian manufacturing services up to 2000L.”

KBI will also continue to support other ongoing drug development programs for Merck from its two North Carolina facilities.

To date, KBI has helped to advance more than 220 molecules in 55 unique health indications for over 170 clients around the world.

With the addition of these expanded microbial capabilities, KBI is well positioned to continue to accelerate an even broader range of drug development programs for its global client base.

Advertisement